drugset / Trial / NCT00423098

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

NCT00423098

Phase 2 Completed 81 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will investigate the efficacy and safety of enteric-coated mycophenolate sodium in combination with two different corticosteroid (CS) regimes for the induction of remission of a lupus nephritis flare. Patients will be randomly allocated to standard CS regimen (group I) or to a reduced dose CS regimen (group II)

Timeline

Start
2007-02
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown 2160 mg Oral
Subject Prednisone Other / unclassified 0.5 mg/kg Oral
Subject Prednisone Other / unclassified 1 mg/kg Oral
Background Methylprednisolone Other / unclassified 0.5 g Intravenous

Indications